{
  "id": 20876638,
  "title": "Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027",
  "url": "https://urgent.news/2026/11/20/moderna-vs-biontech-why-only-1-is-a-buy-heading-into-2027",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-20T08:55:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/11/20/moderna-vs-biontech-why-only-1-is-a-buy-heading-in/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "In 2026, Moderna (MRNA) and BioNTech (BNTX) are two mRNA companies that have transitioned beyond their initial focus on coronavirus vaccines. While both have faced challenges due to the vaccine's limited lifespan, they have ventured into oncology. Moderna's personalized cancer vaccine, intismeran, is in four phase 3 trials, while BioNTech's lead candidate, pumitamig, is a bispecific antibody progressing through seven global pivotal studies. Despite BioNTech's substantial cash reserves and a promising pipeline, its future hinges on the leadership transition of its CEO and CMO, set to occur by February 1. Conversely, Moderna boasts several commercialized products, with its flu vaccine approved in 2022 and a broader rollout planned for the 2027-2028 respiratory season. Its oncology-focused intismeran has shown promising results in a phase 3 melanoma trial and is being evaluated for other cancers. Moderna's stock has also surged, driven by investor confidence in its diversified portfolio. For these reasons, Moderna is recommended as the better investment between the two.",
  "summary": "One of these mRNA pioneers has the products and pipeline to drive growth.",
  "key_points": [
    "Moderna and BioNTech transitioned beyond coronavirus vaccines in 2026",
    "BioNTech's future depends on CEO and CMO leadership transition by Feb 1",
    "Moderna has commercialized flu vaccine and advancing intismeran in oncology"
  ],
  "editors_take": "Moderna’s diversified commercial portfolio and advanced oncology trials offer more stability for investors than BioNTech’s promising pipeline, which faces immediate risks from an upcoming leadership transition.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}